Establishment and application of HBV (Hepatitis B Virus) specific depletion type CD8 + T cell mouse model
Through HBV antigen peptide immunity and bone marrow adoptive transplantation technology, a mouse model of HBV-specific depletion CD8+ T cell was established, solving the problem that the existing model cannot simulate chronic hepatitis B T cell depletion, and achieving efficient HBV-specific T cell Cell depletion research and new drug development provide convenient research tools for the field of immunization of hepatitis B infection.
Patent Information
- Application Number
- CN202411084283.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-08-08
AI Technical Summary
The existing HBV-specific CD8+ T cell mouse model cannot effectively simulate the exhaustion status of T cells in chronic hepatitis B, and the existing model is complex and costly, making it difficult to conduct liver and systemic immunity studies under HBV infection.
CD45.1 mice were immunized by HBV antigen peptides, their bone marrow was isolated and adopted to CD45.2 transgenic mice irradiated by medullary irradiation, and a HBV-specific depleted CD8+ T cell mouse model was established, using flow The immunometric indicators of the model were evaluated in combination with the detection combination. After successful construction, it was used to study the depletion mechanism of HBV-specific CD8+ T cells and a new target for severe diagnosis and treatment of chronic hepatitis B.
The established model has a high HBV-specific T cell depletion phenotype, which is suitable for studying the T cell depletion mechanism and new drug development in the context of chronic hepatitis B, and provides convenient and economical HBV infection immune research tools.
Smart Images

Figure HDA0004984718140000011 
Figure HDA0004984718140000012 
Figure HDA0004984718140000021
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology inventions and relates to the establishment and application of a HBV-specific exhausted CD8+ T cell mouse model. That is, mice with HBV-specific immunity are obtained by immunizing CD45.1 mice with HBV antigen peptides, and then their bone marrow is separated and adoptively transplanted to CD45.2 HBV transgenic mice that have undergone myeloablation and irradiation, thereby establishing a HBV-specific exhausted CD8+ T cell mouse model. Background Art
[0002] Hepatitis B virus (HBV) infection is an important issue affecting human health. Animal models are important for understanding the pathophysiology of HBV infection, the mechanisms of viral replication, hepatocyte damage and liver fibrosis that occur during the process, and drug efficacy evaluation.
[0003] The key role played by T cell responses in clearing HBV infection has been widely reported. Acute hepatitis B infection induces a strong and multifunctional CD8+ T cell response, while chronic hepatitis B infection causes HBV-specific CD8+ T cells to be affected in many ways, resulting in a decrease in number, functional inhibition, and inability to effectively clear the virus. And as the infection progresses, exhausted HBV-specific CD8+ T cells cannot effectively clear HBV, and repeated inflammation leads to tissue damage, which may eventually progress to cirrhosis and liver cancer. Therefore, in recent years, research on the body's immune exhaustion caused by persistent HBV infection has become a hot topic.
[0004] Since HBV cannot naturally infect mice, even if transgenic mice can express HBV-related components, they will not form specific CD8+ T cells against HBV. In addition, although the HBV plasmid high-pressure hydrodynamic method can make mice express HBV components in a short period of time and cause HBV-specific CD8+ T cell responses, it will not form an exhaustion phenotype due to acute infection. Although the humanized human-mouse liver chimeric mouse model can successfully construct a humanized immune system and can achieve HBV infection, the complex modeling process, the difficulty in sourcing human hepatocytes, and the extremely high cost limit the study of HBV-related immune exhaustion. Although the AAV-HBV-1.3 virus can make mice express HBV for a long time and can also produce HBV-specific CD8+T cell exhaustion, its abundance is extremely low, which is not conducive to further research on the mechanism of HBV-specific CD8+T cell exhaustion in the later stage, and it is also impossible to study the liver and systemic immunity under HBV infection. Therefore, the construction of a convenient and low-cost HBV-specific CD8+ T cell exhaustion mouse model is crucial for HBV-related infection immunity research. Summary of the invention
[0005] The purpose of the present invention is to address the problem of lack of mouse models for studying the mechanism of hepatitis B immune exhaustion, and to provide a method for establishing a HBV-specific exhausted CD8+ T cell mouse model, which is achieved through the following technical solutions:
[0006] First, mice with HBV-specific immunity were established. HBV HBsAg (S190-197: VWLSVIWM) and HBcAg (Precore47-56: FLPSDFFPSV) antigen peptides were subcutaneously injected into the flank of CD45.1 C57 mice. The antigen peptide formula ratio was as follows: Peptide 50μg + Poly I:C 50μg + α-CD40 50μg dissolved in 200μl PBS). The second immunization was performed after an interval of 28-30 days. 28-30 days after the second immunization, the peripheral blood mononuclear cells (PBMCs) of the mice were separated, and HBV-specific CD8+ T cells were detected using flow cytometry combination 1 as shown below. The release of IFN-γ was detected after stimulation with HBsAg (S190-197: VWLSVIWM) and HBcAg (Precore47-56: FLPSDFFPSV) antigen peptides, indicating that CD45.1 mice with HBV-specific immunity can be obtained after two immunizations.
[0007] Flow cytometry combination 1: APC-Cy7-NIR; FITC-CD45.1; Percp-cy5.5-CD44; APC-IFN-γ; BV605-CD8; AlexFlour700-B220
[0008] Then, myeloablation of CD45.2 transgenic mice expressing HBV liver specifically was performed. The specific plan was to prepare HBV liver-specific expression mice (C57BL / 6J-Tg(Alb1HBV)44Bri / J, from JacksonLab) about 5 weeks old, and irradiate them with an X-ray irradiator (Rs2000) at a dose of 4.5Gy for myeloablation the day before bone marrow transplantation. After the treatment, they were returned to the animal room for overnight feeding.
[0009] Then bone marrow transplantation was performed to construct an HBV-specific exhausted CD8+ T cell mouse model. The specific plan is to first prepare crude fiber paper, 1.5ml centrifuge tubes, and 200μl centrifuge tubes (with a needle punched in the bottom) for the experiment, place them in a sterilization bag and sterilize them at 120 degrees Celsius for 30 minutes, then bake them in an oven for use; prepare cell reselection solution (1640 culture medium + 1% calf serum + 1% antibiotics (streptomycin and penicillin); flow elution staining solution (PBS + 1% BSA). Then, on the day of transplantation, CD45.1 mice immunized with HBV antigen peptides were killed, and the femurs and tibias of the mice were aseptically separated and cut open at both ends with surgical scissors to expose the bone cavity. The exposed bone cavity was then The femur and tibia were placed in a 200μl centrifuge tube with a small hole at the bottom, and then the 200μl centrifuge tube was placed in a 1.5ml centrifuge tube and centrifuged at 4 degrees 4000g for 40 seconds. At this time, the femur and tibia in the 200μl centrifuge tube were white, and there was no red bone marrow in the bone cavity. There were a large number of red cell clumps at the bottom of the 1.5ml centrifuge tube. The red blood cells were removed with red blood cell lysis solution, and the remaining cells were filtered through a 70μM filter. After cell counting, 1.0×10 bone marrow cells were transplanted into irradiated myeloablated HBV liver-specific CD45.2 transgenic mice by orbital injection. 6 / mice.
[0010] Finally, flow cytometry was used to evaluate the relevant immune indicators of the HBV-specific exhausted CD8+ T cell mouse model. The specific plan is that blood is collected every week thereafter to observe the proliferation and differentiation of CD8+ T cells transplanted into the recipient mice by flow cytometry. The mice were killed on the 28th day and the liver-infiltrating T cells were isolated. They were cultured for 4-5 hours by in vitro stimulation with HBV peptides and detected using the flow cytometry combination 2 shown below combined with APC-IFN-γ. The Ly108-Tim3+ positive ratio of IFN-γ-positive cells was analyzed to evaluate the degree of exhaustion of HBV-specific CD8+ T cells. The flow cytometry analysis results showed that the proportion of CD8+; Ly108-; Tim3+ T cell subpopulations in the exhausted model mice was significantly increased compared with the control group, indicating that the model was successfully constructed ( Figure 3 ).
[0011] Flow cytometry combination 2: APC-Cy7-NIR; FITC-CD45.1; Percp-cy5.5-CD44; PE-Ly108; BV421-Tim-3; BV605-CD8; AlexFlour700-B220
[0012] Another object of the present invention is to provide the application of the mouse model in the study of the exhaustion mechanism of HBV-specific CD8+ T cells and the discovery of new targets for the diagnosis and treatment of severe chronic hepatitis B, including liver failure.
[0013] The present invention obtains mice with HBV-specific immunity by immunizing CD45.1 mice with HBV antigen peptides, and then isolates their bone marrow for adoptive transplantation to CD45.2 HBV transgenic mice that have undergone myeloablation and irradiation, thereby constructing HBV-specific CD8+ T cell-depleted mice. The establishment of this model can provide a powerful tool for the study of the exhaustion mechanism of HBV-specific CD8+ T cells and the discovery of new targets for the diagnosis and treatment of severe chronic hepatitis B.
[0014] Compared with the prior art, the present invention has the following beneficial effects: 1. The HBV-specific exhausted T cell mouse model established by the method has a higher level of HBV-specific T cells; 2. The HBV-specific T cell exhaustion phenotype in the model is significant; 3. The mouse model can be applied to the study of the formation mechanism of T cell exhaustion in the context of chronic hepatitis B; 4. The mouse model can be applied to the study of new targets and new drugs for HBV-specific CD8+ T cell exhaustion; 5. The mouse model is helpful for the study of mechanisms and new diagnostic and treatment technologies in the field of hepatitis B infection immunity. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 .Flowchart for the construction of HBV-specific CD8+ T cell-depleted mice.
[0016] Figure 2 .On the 57th day after mice were immunized twice with HBV polypeptide, peripheral blood was collected for flow cytometry detection of HBV-specific CD8+ T cells, among which 9.98% of CD8+ T cells secreted IFN-γ after being stimulated by HBsAg polypeptide, indicating successful immunization.
[0017] Figure 3 .Flow cytometric detection results of exhausted phenotype of CD8+ T cells infiltrating mouse liver 28 days after bone marrow transplantation, in which the proportion of stem phenotype (TIM3-; Ly108+ cells) in CD8+ T cells of mouse bone marrow transplanted with HBV polypeptide immunization was significantly reduced compared with that in CD8+ T cells of mouse bone marrow transplanted without HBV polypeptide immunization, while the proportion of exhausted phenotype subpopulation (TIM3+; Ly108- cells) was increased.
[0018] Figure 4 . Liver enzymes and the proportion of HBV-specific CD8+ T cells in mice depleted of HBV-specific CD8+ T cells in the ConA-induced mouse liver failure model. DETAILED DESCRIPTION
[0019] The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.
[0020] Example 1 Preparation of HBV-specific immune mice:
[0021] according to Figure 1 The process shown firstly prepares HBV-specific immune mice. 1. Commercially synthesized HBV S and C epitope peptides are epitope peptides specifically recognized by CD8+T cells, and their sequences are HBsAg (S190-197: VWLSVIWM) and HBcAg (Precore47-56: FLPSDFFPSV), respectively. PBS is prepared into 200μl immune injection solution, which contains 50μg of peptide mixture, 50μg of Poly I:C, and 50μg of anti-mouse CD40 antibody.
[0022] 2. Subcutaneous injection immunization of mice: CD45.1 genotype C57 mice, about 5 weeks old, were injected with 200 μl of immunization solution at a single point subcutaneously on the hind buttocks. A second booster injection was given 28 days later. Orbital blood was collected on the 27th and 58th days for flow cytometry.
[0023] 3. Analysis of HBV-specific CD8+ T cell abundance: After the red blood cells were lysed from the collected peripheral blood, PBMC were reselected in FACS buffer, centrifuged at 800g for 1 minute and the supernatant was discarded, the precipitate was resuspended in the premix of flow cytometry combination 1, stained at 4 degrees for 20 minutes, then 200μl FACS buffer was added and centrifuged at 800g for 1 minute and the supernatant was discarded, repeated once and centrifuged, the precipitate was resuspended in 400μl FACS buffer for flow cytometry detection. Figure 2 As shown, after HBV peptide stimulation, CD8+ T cell subsets secreting IFN-γ were detected in PBMCs of mice immunized with HBV antigen peptides, indicating that HBV immunization was successful and specific CD8+ T cells targeting HBV peptides were obtained.
[0024] Example 2 Establishment and evaluation of HBV-specific exhausted CD8+ T cell mouse model:
[0025] according to Figure 1 The process shown continues with the establishment of a HBV-specific CD8+ T cell exhausted mouse model and flow cytometric assessment of the T cell exhaustion phenotype. 1. HBV-immunized mice were killed after positive peripheral blood HBV-specific CD8+ T cells were detected by flow cytometry. The lower limbs of the mice were separated aseptically, the attached muscles were removed, and the femur and tibia were cut open to expose the bone marrow cavity. The cut femur and tibia were placed in a 200μl small centrifuge tube (with a pre-opened bottom), and then placed in a 1.5ml centrifuge tube and centrifuged at 4000g for 40 seconds in a 4-degree centrifuge. The red cell mass at the bottom of the 1.5ml centrifuge tube was retained. The red blood cells were removed with red blood cell lysis buffer, the remaining cells were centrifuged and resuspended in PBS, and the final count was adjusted to a cell concentration of 5.0×10 6 / ml and keep on ice until use.
[0026] 2. The recipient mice with liver-specific expression of HBV were anesthetized using a mouse anesthesia system and 1.0×10 6 After the mice regained consciousness at room temperature, they were placed back into the barrier for feeding.
[0027] 3. On the 28th day after transplantation, peripheral blood was collected from the eye sockets, and peptide stimulation solution (0.2 μl of 1 mg / ml HBV peptide + 0.1 μl of 10 mg / ml DNA25 solution + 0.1 μl of brefeldinA + 0.1 μl of monesin) was added to the PBMC after red blood cell lysis and removal of red blood cells, and the cells were incubated in a 37-degree cell incubator for 4-5 hours.
[0028] 4. After stimulation, the cells were centrifuged at 800 g for 1 minute, the supernatant was discarded, the pellet was washed twice with FACS, and then resuspended with flow cytometry antibody premix 2, stained at 4 degrees for 20 minutes, and then 200 μl FACS buffer was added and centrifuged at 800 g for 1 minute, and the supernatant was discarded. Repeat once and then centrifuge.
[0029] 5. After centrifugation, discard the supernatant, resuspend the pellet with 200 μl BD CytoPerm / CytoFix, and incubate at 4 degrees for 20 minutes to permeabilize the membrane.
[0030] 6. Wash twice with 200 μl BD Perm washing solution.
[0031] 7. Prepare APC-IFN-γ premix with 50 μl BD Perm washing solution, adjust to 30 μl with a dispenser, pipette and aspirate repeatedly 5 times until there is no precipitation, and incubate at 4 degrees for 20 minutes.
[0032] 8. Wash twice with 200 μl BD Perm washing solution.
[0033] 9. Wash the pellet again with FACS buffer.
[0034] 10. Finally, resuspend the precipitate in 400 μl FACS buffer for flow cytometry detection.
[0035] like Figure 3 As shown in the figure, HBV-specific CD8+ T cells infiltrating the liver of mice on day 28 after bone marrow transplantation showed an exhausted phenotype, that is, the proportion of Ly108-;TIM-3+ CD8+ T cell subsets increased significantly, indicating that the HBV-specific exhausted CD8+ T cell mouse model was successfully established.
[0036] Example 3 Application of HBV-specific CD8+ T cell depletion mouse model in the study of hepatitis B liver failure Blood samples were collected from HBV-specific CD8+ T cell depletion mice and control mice one day before the experiment to test liver function indicators such as ALT and AST. After confirming that there was no difference between the two, 15 mg / kg ConA was injected into the tail vein. Peripheral blood, spleen, and liver tissue samples were collected 6 hours after modeling to evaluate liver function. The results showed that HBV-specific CD8+ T cell depletion mice had more severe liver damage ( Figure 4 ), suggesting that the mice can simulate chronic hepatitis B liver failure.
Claims
1. Construction of a HBV-specific exhausted CD8+T cell mouse model, characterized in that: This is achieved through the following scheme: (1) establishing mice with HBV-specific immunity, using HBV HBsAg and HbcAg antigen peptides to subcutaneously inject CD45.1 C57 mice, and performing a second immunization 28-30 days later. 28-30 days after the second immunization, separating peripheral blood mononuclear cells from the mice, and using flow cytometry combination 1 to detect HBV-specific CD8+T cells. After stimulation with HbsAg and HbcAg antigen peptides, the release of IFN-γ was detected, indicating that CD45.1 mice with HBV-specific immunity were obtained after two immunizations; (2) Myeloablation of CD45.2 transgenic mice expressing HBV liver-specifically. Prepare 5-week-old mice expressing HBV liver-specifically. One day before bone marrow transplantation, perform myeloablation with an X-ray irradiator at a dose of 4.5 Gy and then feed them overnight. (3) Perform bone marrow transplantation to construct a HBV-specific exhausted CD8+T cell mouse model. First, prepare experimental coarse fiber paper, 1.5 ml centrifuge tubes, and 200 μl centrifuge tubes with small holes at the bottom. Place them in a sterilization bag and sterilize them at 120 degrees Celsius for 30 minutes, then bake them in an oven for later use. Prepare cell reselection fluid and flow elution staining fluid, and then aseptically separate the femur and tibia of CD45.1 mice immunized with HBV antigen peptides on the day of transplantation to expose the bone cavity. Then, place the exposed femur and tibia on the bottom of the sterile bag. Place the 200μl centrifuge tube with a small hole on the top of the tube, and then place the 200μl centrifuge tube in a 1.5ml centrifuge tube and centrifuge at 4 degrees 4000g for 40 seconds. At this time, the femur and tibia in the 200μl centrifuge tube are white, there is no red bone marrow in the bone cavity, and there are a lot of red cell blocks at the bottom of the 1.5ml centrifuge tube. Remove the red blood cells with red blood cell lysis solution, and pass the remaining cells through a 70μM filter. After the cell count, transplant 1M bone marrow cells into HBV liver-specific CD45.2 transgenic mice that have undergone irradiated myeloablation; (4) Flow cytometry was used to evaluate the relevant immune indicators of the HBV-specific exhausted CD8+T cell mouse model. Blood was collected weekly to observe the proliferation and differentiation of CD8+T cells transplanted into recipient mice by flow cytometry. On the 28th day, liver-infiltrating T cells were isolated and cultured for 4-5 hours after in vitro stimulation with HBV peptides. Flow cytometry combination 2 was used in combination with APC-IFN-γ to detect the degree of exhaustion of HBV-specific CD8+T cells by analyzing the Ly108-Tim3+ positive ratio of IFN-γ-positive cells. The flow cytometry analysis results showed that the proportion of CD8+Ly108-Tim3+T cell subpopulations in the exhausted model mice was significantly increased compared with the control group, indicating that the model was successfully constructed.
2. The construction according to claim 1, characterized in that The antigen peptide formula ratio in step (1) is: Peptide 50 μg + Poly I:C 50 μg + α-CD40 50 μg dissolved in 200 μl PBS.
3. The construction according to claim 1, characterized in that The flow cytometry detection combination 1 in step (1) is: APC-Cy7-NIR; FITC-CD45.1; Percp-cy5.5-CD44; APC-IFN-γ; BV605-CD8; AlexFlour700-B220.
4. The construction according to claim 1, characterized in that The HBV liver-specific expression mice in step (2) are C57BL / 6J-Tg(Alb1HBV)44Bri / J, which are from Jackson Lab.
5. The construction according to claim 1, characterized in that The configuration of the cell reselection solution in step (3) is: 1640 culture medium + 1% calf serum + 1% antibiotic, wherein the antibiotic is streptomycin or penicillin; the flow elution staining solution is PBS + 1% BSA.
6. The construction according to claim 1, characterized in that The flow cytometry detection combination 2 in step (4) is: APC-Cy7-NIR; FITC-CD45.1; Percp-cy5.5-CD44; PE-Ly108; BV421-Tim-3; BV605-CD8; AlexFlour700-B220.
7. Use of the mouse model constructed according to claim 1 in the study of the exhaustion mechanism of HBV-specific CD8+T cells.
8. The mouse model constructed according to claim 1 is used in the discovery of new targets for the diagnosis and treatment of severe chronic hepatitis B, including liver failure.
Citation Information
Patent Citations
Establishment of HBV (Hepatitis B Virus) persistent infection and fibrosis mouse model
CN103329852A
T-cell exhaustion state-specific gene expression regulators and uses thereof
US20210309965A1
Hepatic Stem-Like Cells for the Treatment and / or the Prevention of Liver Disorders
US20230407264A1
Modified immune cell targeting hepatitis b surface antigen and medical use thereof
WO2024049348A1
Cited By
In-vitro T cell depletion function evaluation method and application thereof in immunotherapy curative effect prediction
CN122171424A
